Cover Image
市場調查報告書

全球心房纖維顫動治療市場

Global Atrial Fibrillation Market 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 232658
出版日期 內容資訊 英文 67 Pages
訂單完成後即時交付
價格
Back to Top
全球心房纖維顫動治療市場 Global Atrial Fibrillation Market 2015-2019
出版日期: 2015年01月28日 內容資訊: 英文 67 Pages
簡介

全球心房纖維顫動治療市場,以全球人口的高齡化為背景,從2014年到2019年,預計以11.05%的年複合成長率擴大。

本報告提供全球心房纖維顫動治療市場調查、這些市場趨勢與成長預測、主要供應商分析等。

第1章 摘要整理

第2章 簡稱清單

第3章 調查範圍

  • 市場概要
  • 主要的產品

第4章 產品簡介

  • Pradaxa/ Prazaxa
  • Xarelto
  • Multaq

第5章 市場調查手法

  • 市場調查流程
  • 調查手法

第6章 簡介

第7章 疾病概要

  • 疾病的理解
  • 分類
  • 病理學
  • 原因
  • 流行病學
  • 管理
  • 經濟負擔

第8章 市場形勢

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第9章 各類藥物的市場分類

  • 坑凝固藥
  • 抗心律不整藥

第10章 地理區分

第11章 購買標準

第12章 市場成長因素

第13章 成長因素與其影響

第14章 市場課題

第15章 成長因素與課題的影響

第16章 市場趨勢

第17章 趨勢與其影響

第18章 業者情勢

  • 競爭模式
    • 主要消息
    • M&A
  • 市場佔有率分析
    • Boehringer Ingelheim
    • Sanofi
    • Janssen Pharmaceuticals
  • 其他卓越供應商

第19章 主要供應商分析

  • Boehringer Ingelheim
  • Janssen Pharmaceuticals
  • Sanofi

第20章 相關報告

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: IRTNTR5053

About Atrial Fibrillation

According to the NHLBI of the NIH in the US, atrial fibrillation is one of the commonest type of arrhythmia. Atrial fibrillation is similar to another type of arrhythmia of the heart, superventricular tachycardia. The chief difference between these two types of arrhythmia is the consistency of the beats. In superventricular tachycardia, the heart beats are regular and at a very fast pace. Patients with atrial fibrillation experience fast and irregular heartbeats. In patients with atrial fibrillation, electrical signals travel rapidly in an uncontrolled way, which causes convulsion, palpitation or contraction in the atria of the heart. Blood is accumulated inside the atrial chambers, instead of flowing to the ventricular chambers. In this case, blood is not pumped into the ventricles fully. Also, the quantity of blood pumped out of the ventricles to the body is irregular and centered on the arbitrary atrial strokes. This can lead to the formation of blood clot in the atria. Stroke occurs in case the clot moves to the brain, which can cause death of an individual. In atrial fibrillation, the ventricles might beat for 100 to 175 times per minute, which is a stark contrast to the normal heart rate of 60 to 100 beats per minute. Atrial fibrillation is more common in older people and is detected using an ECG reading to find out the abnormalities of the electric signal. Some of the symptoms of atrial fibrillation are rapid and irregular heartbeat, palpitations, dizziness, sweating, chest pain, breathlessness, fatigue, and sometimes loss of consciousness.

TechNavio's analysts forecast the Global Atrial Fibrillation market to grow at a CAGR of 11.05 percent over the period 2014-2019.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Atrial Fibrillation market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various drugs such as anti-arrythmics and anticoagulants used in the treatment of atrial fibrillation.

The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the Global Atrial Fibrillation market. The vendor landscape section includes a market share analysis of the major vendors along with the performances of their product portfolios. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.

TechNavio's report, Global Atrial Fibrillation Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Atrial Fibrillation market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • Boehringer Ingelheim
  • Janssen Pharmaceuticals
  • Sanofi

Other Prominent Vendors

  • ARCA Biopharma
  • Armetheon
  • Baxter
  • Bristol-Myers Squibb
  • ChanRx
  • Daiichi Sankyo
  • Gilead Sciences
  • HUYA Biosciences
  • Menarini
  • Pfizer
  • Pierre Fabre
  • Servier
  • Xention

Market Driver

  • Growing Patient Base
  • For a full, detailed list, view our report

Market Challenge

  • High Cost of Therapy
  • For a full, detailed list, view our report

Market Trend

  • Shifting Focus on Emerging Markets
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Product Profiles

    • 04.1.1. Pradaxa/ Prazaxa
    • 04.1.2. Xarelto
    • 04.1.3. Multaq

05. Market Research Methodology

  • 05.1. Market Research Process
  • 05.2. Research Methodology

06. Introduction

07. Disease Overview

  • 07.1. Understanding the Disease
  • 07.2. Classification
  • 07.3. Pathophysiology
  • 07.4. Causes
  • 07.5. Epidemiology
  • 07.6. Management
  • 07.7. Economic Burden

08. Market Landscape

  • 08.1. Market Overview
  • 08.2. Market Size and Forecast
  • 08.3. Five Forces Analysis

09. Market Segmentation by Class of Drugs

    • 09.1.1. Anticoagulants
    • 09.1.2. Anti-arrythmics

10. Geographical Segmentation

11. Buying Criteria

12. Market Growth Drivers

13. Drivers and their Impact

14. Market Challenges

15. Impact of Drivers and Challenges

16. Market Trends

17. Trends and their Impact

18. Vendor Landscape

  • 18.1. Competitive Scenario
    • 18.1.1. Key News
    • 18.1.2. Mergers and Acquisitions
  • 18.2. Market Share Analysis 2014
    • 18.2.1. Boehringer Ingelheim
    • 18.2.2. Sanofi
    • 18.2.3. Janssen Pharmaceuticals
  • 18.3. Other Prominent Vendors

19. Key Vendor Analysis

  • 19.1. Boehringer Ingelheim
    • 19.1.1. Key Facts
    • 19.1.2. Business Overview
    • 19.1.3. Business Segmentation by Revenue 2013
    • 19.1.4. Business Segmentation by Revenue 2012 and 2013
    • 19.1.5. Geographical Segmentation by Revenue 2013
    • 19.1.6. Business Strategy
    • 19.1.7. Recent Developments
    • 19.1.8. SWOT Analysis
  • 19.2. Janssen Pharmaceuticals
    • 19.2.1. Key Facts
    • 19.2.2. Business Overview
    • 19.2.3. Recent Developments
    • 19.2.4. SWOT Analysis
  • 19.3. Sanofi
    • 19.3.1. Key Facts
    • 19.3.2. Business Description
    • 19.3.3. Business Segmentation
    • 19.3.4. Revenue by Business Segmentation
    • 19.3.5. Revenue Comparison 2012 and 2013
    • 19.3.6. Sales by Geography
    • 19.3.7. Business Strategy
    • 19.3.8. Key Developments
    • 19.3.9. SWOT Analysis

20. Other Reports in this Series

List of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Types of Atrial Fibrillation
  • Exhibit 3: Risk Factors Associated with Atrial Fibrillation
  • Exhibit 4: Management of Atrial Fibrillation
  • Exhibit 5: Economic Burden of Atrial Fibrillation
  • Exhibit 6: Global Atrial Fibrillation Market 2014-2019 (US$ million)
  • Exhibit 7: Challenges and Drivers of Global Atrial Fibrillation Market
  • Exhibit 8: Global Atrial Fibrillation Market Segmentation by Class of Drugs
  • Exhibit 9: Sub-classification of Anti-arrythmics
  • Exhibit 10: Segmentation of Global Atrial Fibrillation Market by Geography 2014
  • Exhibit 11: Buying Criteria of the Global Atrial Fibrillation market
  • Exhibit 12: World's Population Aged 60 and Above (2010-2020)
  • Exhibit 13: The Global Prevalence of Atrial Fibrillation 2006-2016 (Million)
  • Exhibit 14: Drivers and their Impact on the Key Customer Category of the Global Atrial Fibrillation market
  • Exhibit 15: Drivers and their Impact on Geographies in Global Atrial Fibrillation Market
  • Exhibit 16: Global Atrial Fibrillation Market Share Analysis 2014
  • Exhibit 17: Boehringer Ingelheim: Business Segmentation by Revenue 2013
  • Exhibit 18: Boehringer Ingelheim: Business Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 19: Boehringer Ingelheim: Geographical Segmentation by Revenue 2013
  • Exhibit 20: Sanofi SA: Business Segmentation
  • Exhibit 21: Sanofi SA: Revenue by Business Segmentation 2013
  • Exhibit 22: Sanofi SA: Revenue by Business Segmentation 2012 and 2013 (US$ million)
  • Exhibit 23: Sanofi SA: Sales Revenue by Geographical Segmentation 2013
Back to Top